In a open-label pilot study published in *Clinical Therapeutics*, researchers investigated the effects of a dietary supplement containing the anti-inflammatory flavonoid luteolin in children with autism spectrum disorder (ASD).

The 26-week study included children diagnosed with ASD who received a formulation containing luteolin (a flavonoid found in celery and chamomile), along with quercetin and rutin, designed to enhance absorption and provide antioxidant and anti-inflammatory effects. Because the study was open-label, all participants received the supplement and there was no placebo control group.

Behavioral changes were measured using standardized tools, including the Aberrant Behavior Checklist (ABC) and the Vineland Adaptive Behavior Scales (VABS). After 26 weeks, researchers reported reductions of approximately 26% to 35% in ABC subscales, including lethargy (social withdrawal), stereotypy (repetitive behaviors), hyperactivity, and inappropriate speech. Improvements were also observed in adaptive functioning domains such as communication and daily living skills. However, as a small pilot study without a control group, the findings are considered preliminary and require confirmation in larger randomized controlled trials.

PMID: 23688534